| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $263,223 | 4 | 100 |
| Aslan Fred | President and CEO | 0 | $0 | 4 | $263,223 | $-263,223 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Artiva Biotherapeutics, Inc. have bought $0 and sold $263,223 worth of Artiva Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Artiva Biotherapeutics, Inc. have bought $165M and sold $263,223 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,333,333 shares for transaction amount of $100M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑07‑22.
| 2025-12-15 | Sale | Aslan Fred | President and CEO | 3,187 0.0175% | $6.00 | $19,122 | -23.41% | |
| 2025-11-17 | Sale | Aslan Fred | President and CEO | 6,375 0.0197% | $3.38 | $21,522 | +31.62% | |
| 2025-10-17 | Sale | Aslan Fred | President and CEO | 25,500 0.1402% | $6.00 | $153,000 | -25.04% | |
| 2025-08-15 | Sale | Aslan Fred | President and CEO | 25,500 0.0638% | $2.73 | $69,579 | +50.73% | |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. | 8.33M 91.6587% | $12.00 | $100M | -44.44% | |||
| 2024-07-22 | Huh Yong-Jun | director | 2.08M 22.9147% | $12.00 | $25M | -44.44% | ||
| 2024-07-22 | GC Corp. | 10 percent owner | 2.08M 22.9147% | $12.00 | $25M | -44.44% | ||
| 2024-07-22 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 416,666 4.5829% | $12.00 | $5M | -44.44% | ||
| 2024-07-22 | 5AM Partners VI, LLC | 10 percent owner | 833,333 9.1659% | $12.00 | $10M | -44.44% |
| Aslan Fred | President and CEO | 1209948 4.8953% | $15.18M | 0 | 4 | |
| RA CAPITAL MANAGEMENT, L.P. | 8693579 35.1729% | $109.1M | 1 | 0 | <0.0001% | |
| Huh Yong-Jun | director | 3306900 13.3792% | $41.5M | 1 | 0 | <0.0001% |
| GC Corp. | 10 percent owner | 3306900 13.3792% | $41.5M | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 1936637 7.8353% | $24.3M | 1 | 0 | <0.0001% |
| 5AM Partners VI, LLC | 10 percent owner | 1182054 4.7824% | $14.83M | 1 | 0 | <0.0001% |
$27,004,904 | 102 | 5.82% | $331.11M | |
$24,436,687 | 43 | -29.99% | $308.9M | |
$130,095 | 43 | 45.19% | $337.33M | |
$167,815,836 | 33 | 9.57% | $247.43M | |
$3,668,031 | 23 | 2.05% | $313.77M | |
$1,447,973 | 17 | 13.95% | $309.83M | |
$135,812,721 | 14 | 17.52% | $329.12M | |
$1,037,470 | 13 | 78.00% | $251.54M | |
$10,399,379 | 13 | 13.60% | $325.27M | |
$170,425 | 10 | -16.01% | $268.03M | |
$6,847,110 | 9 | 5.96% | $341.57M | |
$13,043,783 | 8 | 732.82% | $331.15M | |
$272,982 | 6 | -28.53% | $271.52M | |
Artiva Biotherapeutics, Inc. (ARTV) | $164,999,952 | 5 | -44.44% | $310.19M |
$20,729,984 | 5 | 51.71% | $268.11M | |
$32,289,200 | 3 | -5.46% | $283.63M | |
$4,888,000 | 3 | -20.50% | $310.52M | |
$15,551,156 | 3 | 98.82% | $319.19M | |
$12,498 | 2 | 39.61% | $248.51M |
| Increased Positions | 10 | +15.87% | 732,601 | +4.04% |
| Decreased Positions | 27 | -42.86% | 2M | -10.63% |
| New Positions | 6 | New | 468,430 | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 46 | -26.98% | 17M | -6.59% |